Barry Ticho - Jan 2, 2024 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Signature
/s/ Stephen Tulipano, Attorney-in-Fact
Stock symbol
STOK
Transactions as of
Jan 2, 2024
Transactions value $
-$57,352
Form type
4
Date filed
1/4/2024, 04:38 PM
Previous filing
Dec 5, 2023
Next filing
Feb 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STOK Common Stock Sale -$57.4K -10K -37.06% $5.74 17K Jan 2, 2024 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted on September 14, 2023 by the reporting person.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.15 to $5.97 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The reported total includes an additional 1,086 shares of the issuer's stock that were acquired by the reporting person through the issuer's employee stock purchase plan in exempt transactions pursuant to Rule 16b3(c).